The most common tirzepatide side effects are gastrointestinal: nausea affects 25-29% of patients, diarrhea 19-23%, vomiting 8-13%, and constipation 11-17%, depending on dose. Most are mild to moderate and concentrate during the 20-week dose-escalation period. Serious side effects exist but are uncommon: acute pancreatitis, severe gastrointestinal reactions, gallbladder disease, kidney injury from dehydration, anaphylaxis, and the boxed-warning thyroid C-cell tumor risk.1 This breakdown covers what the FDA-approved Zepbound label reports, sorted by dose and flagged when a side effect is serious enough to watch carefully.
We cover Zepbound (tirzepatide for weight management and obstructive sleep apnea in adults with obesity) as the source of most incidence data, since Zepbound is where rates are cleanest. Mounjaro (same molecule, FDA-approved for Type 2 diabetes) has an overlapping profile. Compounded tirzepatide side effects are covered briefly, the active molecule is the same, and class-level reactions are expected, but trial-quality rate data does not exist for compounded preparations. For clinical decisions, talk to a licensed prescriber; this article is for general educational use.
Tirzepatide Side Effects at a Glance
- Most common (≥20%): nausea (25-29%), diarrhea (19-23%). Both are dose-stable after 5 mg.1
- Common (5-19%): constipation (11-17%), vomiting (8-13%), abdominal pain (9-10%), dyspepsia (9-10%), injection site reactions (6-8%), fatigue (5-7%), hypersensitivity reactions (5%), eructation (4-5%), hair loss (4-5%), GERD (4-5%).1
- Less common (1-4%): flatulence, abdominal distension, dizziness, hypotension, dry mouth (1%), dysgeusia (0.4%), dysesthesia (0.2-0.4%).1
- Serious / rare: acute pancreatitis, severe gastrointestinal adverse reactions, acute kidney injury, acute gallbladder disease, anaphylaxis and angioedema, hypoglycemia (with insulin or sulfonylureas), diabetic retinopathy complications, thyroid C-cell tumors (boxed warning from rodent data).1
- Discontinuation rate due to adverse events in SURMOUNT-1 (72-week trial, N=2,539): 4.3% at 5 mg, 7.1% at 10 mg, 6.2% at 15 mg, versus 2.6% placebo.2
- Most side effects appear during dose escalation and decrease over time as the body adapts to tirzepatide's effect on gastric emptying.1
What are the most common tirzepatide side effects?
The FDA-approved Zepbound label reports the following adverse reaction rates from pooled data in SURMOUNT-1 (Study 1) and the Type 2 diabetes + obesity trial (Study 2), combining 2,519 patients randomized to 5 mg, 10 mg, or 15 mg weekly versus 958 placebo-treated patients.1
| Adverse Reaction | Placebo (N=958) | 5 mg (N=630) | 10 mg (N=948) | 15 mg (N=941) |
|---|---|---|---|---|
| Nausea | 8% | 25% | 29% | 28% |
| Diarrhea | 8% | 19% | 21% | 23% |
| Constipation | 5% | 17% | 14% | 11% |
| Vomiting | 2% | 8% | 11% | 13% |
| Abdominal pain | 5% | 9% | 9% | 10% |
| Dyspepsia | 4% | 9% | 9% | 10% |
| Injection site reactions | 2% | 6% | 8% | 8% |
| Fatigue | 3% | 5% | 6% | 7% |
| Hypersensitivity reactions | 3% | 5% | 5% | 5% |
| Eructation (burping) | 1% | 4% | 5% | 5% |
| Hair loss | 1% | 5% | 4% | 5% |
| GERD | 2% | 4% | 4% | 5% |
| Flatulence | 2% | 3% | 3% | 4% |
| Abdominal distension | 2% | 3% | 3% | 4% |
| Dizziness | 2% | 4% | 5% | 4% |
| Hypotension | 0% | 1% | 1% | 2% |
Source: Zepbound Full Prescribing Information, Section 6.1 Clinical Trials Experience, Table 1. Adverse reactions reported in ≥2% of ZEPBOUND-treated patients and greater than placebo, pooled from Studies 1 and 2.1
Four observations sit under this table. First, gastrointestinal reactions dominate, the top four categories (nausea, diarrhea, constipation, vomiting) are all GI. Second, placebo rates are not zero, 8% of placebo patients reported nausea, which means the drug-attributable nausea rate is closer to 17-21 percentage points, not the raw 25-29%. Third, dose-response is modest for most reactions past 5 mg, nausea barely climbs from 25% to 29% across the 3-fold dose range. Fourth, constipation is the one reaction that runs higher at lower doses, likely because 5 mg patients have not adapted to the motility effect as much as 10-15 mg patients who have been on therapy longer.
How common is nausea on tirzepatide?
Nausea is the single most common tirzepatide side effect. In the pooled Zepbound clinical trials, nausea was reported by 25% of patients on 5 mg, 29% on 10 mg, and 28% on 15 mg, compared with 8% of placebo patients.1 The placebo-adjusted rate, the nausea attributable to the drug, is roughly 17 to 21 percentage points.
The FDA label is explicit that "the majority of nausea, vomiting, and/or diarrhea events occurred during dose escalation and decreased over time."1 Mechanistically, tirzepatide slows gastric emptying, so food stays in the stomach longer, which produces the fullness signal that drives appetite reduction and also triggers nausea in susceptible patients. The stomach adapts over weeks, which is why nausea tends to fade after reaching a stable maintenance dose.
If nausea is severe enough to interfere with hydration or eating, clinicians typically recommend holding at the current dose longer rather than escalating, or stepping back to a lower maintenance dose. The Zepbound label explicitly permits staying at 5 mg or 10 mg as a maintenance dose if tolerability is marginal at higher doses.
How common is diarrhea, vomiting, and constipation on tirzepatide?
After nausea, the other three major gastrointestinal reactions have clear rates in the FDA label data:
- Diarrhea: 19% at 5 mg, 21% at 10 mg, 23% at 15 mg (vs 8% placebo). Diarrhea climbs gradually with dose and is the only GI reaction that does so linearly.1
- Vomiting: 8% at 5 mg, 11% at 10 mg, 13% at 15 mg (vs 2% placebo). Vomiting is clearly dose-dependent and is the most likely GI reaction to drive discontinuation at higher doses.1
- Constipation: 17% at 5 mg, 14% at 10 mg, 11% at 15 mg (vs 5% placebo). Constipation runs higher at lower doses, an unusual pattern, probably reflecting earlier-treatment adaptation. Severe constipation and fecal impaction are listed as postmarketing reports.1
Clinically, the GI reactions cluster. Patients who get nausea often also get dyspepsia, eructation (burping), GERD, or abdominal pain, all features of slowed gastric emptying. The full GI reaction rate (any GI adverse event) was 56% at all three doses versus 30% on placebo, per the pooled trial data.1
What are the serious side effects of tirzepatide?
The FDA label describes several rare but clinically important tirzepatide side effects. These are not frequent, but they are the ones worth knowing about because they may require urgent evaluation.
Acute pancreatitis
In pooled SURMOUNT-1 and Study 2 weight-reduction trials, acute pancreatitis was confirmed by adjudication in 0.2% of Zepbound-treated patients versus 0.2% of placebo-treated patients.1 The rate is similar between treatment and placebo in the weight-management trials, but higher in the obstructive sleep apnea trials (0.84 per 100 patient-years versus 0 for placebo). Postmarketing reports include hemorrhagic and necrotizing pancreatitis, sometimes resulting in death.1 Severe abdominal pain radiating to the back is the classic presentation and warrants immediate medical evaluation.
Acute kidney injury due to volume depletion
Acute kidney injury was reported in 0.5% of Zepbound-treated patients versus 0.2% of placebo-treated patients. The mechanism is usually volume depletion from vomiting, diarrhea, or reduced fluid intake.1 Patients with severe GI reactions are at highest risk. Staying hydrated through the titration window is a practical protection.
Acute gallbladder disease
Cholelithiasis (gallstones) was reported in 1.1% of Zepbound-treated patients versus 1% of placebo-treated patients. Cholecystitis (gallbladder inflammation) was reported in 0.7% versus 0.2%, and cholecystectomy in 0.2% versus none.1 Rapid weight loss is a known risk factor for gallstones independent of the drug, and tirzepatide-driven weight loss accelerates this background risk.
Hypersensitivity reactions, including anaphylaxis
Immediate hypersensitivity reactions (within one day of dose administration) occurred in 2.1% of Zepbound-treated patients versus 0.4% of placebo-treated patients. Patients who developed anti-tirzepatide antibodies had a 6.2% hypersensitivity rate versus 3% in antibody-negative patients.1 Postmarketing reports include anaphylaxis and angioedema. Any signs of severe allergic reaction, swelling of the face, lips, or throat; widespread rash; difficulty breathing, are emergency symptoms.1
Thyroid C-cell tumors (boxed warning)
Zepbound carries a boxed warning based on rodent studies showing dose-dependent and treatment-duration-dependent thyroid C-cell tumors in rats and mice. Whether this translates to human risk is unknown; tirzepatide has not been in broad clinical use long enough to fully characterize this. The label contraindicates tirzepatide in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN 2).1
Pulmonary aspiration during anesthesia
Postmarketing reports describe pulmonary aspiration in patients on GLP-1 receptor agonists undergoing elective surgery or procedures requiring general anesthesia or deep sedation. The mechanism is delayed gastric emptying producing retained gastric contents despite pre-operative fasting.1 Disclose tirzepatide to your surgical and anesthesia teams well before any planned procedure.
Does tirzepatide cause hair loss?
Yes, hair loss is a documented tirzepatide side effect, and it is associated with weight reduction rather than the drug alone. In the pooled Zepbound weight-management trials, hair loss was reported by 7.1% of female and 0.5% of male tirzepatide-treated patients, compared with 1.3% of female and 0% of male placebo-treated patients.1 The female rate is more than five times the male rate, which is consistent with the pattern of weight-loss-associated telogen effluvium, the hair-shedding response that follows significant weight change.
The FDA label notes that no Zepbound-treated patients and one placebo-treated patient discontinued therapy due to hair loss, suggesting the reaction is typically not severe enough to stop treatment. Hair loss from weight reduction tends to resolve over months once weight stabilizes.
Does tirzepatide cause injection site reactions?
Injection site reactions, bruising, redness, itching, pain, rash, occurred in 6-8% of Zepbound-treated patients across the 5, 10, and 15 mg doses, compared with 2% of placebo-treated patients.1 The rate was substantially higher in patients who developed anti-tirzepatide antibodies: 11.3% versus 1% in antibody-negative patients.1
Practical mitigation: rotate injection sites across the abdomen, thigh, and upper arm (the three sites the Zepbound label approves). Let the alcohol wipe dry before injecting. If redness persists more than 48 hours, or a reaction spreads beyond the injection site, contact your prescriber. That pattern is not typical and may warrant evaluation.
How many people stop tirzepatide because of side effects?
Treatment discontinuation rates due to adverse events in SURMOUNT-1 (the 72-week phase 3 obesity trial, N=2,539) were:2
- 5 mg weekly: 4.3%
- 10 mg weekly: 7.1%
- 15 mg weekly: 6.2%
- Placebo: 2.6%
Discontinuation due specifically to gastrointestinal adverse reactions scaled with dose in the pooled Zepbound data: 1.9% at 5 mg, 3.3% at 10 mg, 4.3% at 15 mg, versus 0.5% on placebo.1 These are low absolute rates, more than 92% of patients at every dose continued through the trial, but the 10 mg and 15 mg doses carry roughly two to three times the discontinuation risk of placebo.
In a separate lifestyle-intervention lead-in trial (Study 3), 10% of Zepbound-treated patients and 2% of placebo-treated patients discontinued due to adverse reactions.1 That higher overall rate reflects the longer 72-week exposure plus the more intensive behavioral protocol.
Are tirzepatide side effects dose-dependent?
Some are and some are not. The pattern is more complicated than a simple "higher dose = more side effects":
- Clearly dose-dependent: vomiting (8→11→13%), diarrhea (19→21→23%), hypotension (1→1→2%). These track dose upward.
- Dose-stable past 5 mg: nausea, abdominal pain, dyspepsia, injection site reactions, eructation. These plateau after the first therapeutic dose.
- Inversely related to dose: constipation (17→14→11%). Higher doses run lower rates, likely because patients on 10-15 mg have been on therapy longer and the motility effect has stabilized.
- Not strongly dose-dependent: hair loss, fatigue, hypersensitivity reactions, GERD. Rates are similar across doses.
The overall gastrointestinal adverse event rate was 56% at all three doses.1 That means moving from 5 mg to 15 mg does not broadly produce more GI side effects. It changes which ones and how severe they tend to be.
How long do tirzepatide side effects last?
Most tirzepatide side effects are mild to moderate and concentrate during the 20-week dose-escalation period. The FDA label describes the pattern directly: "the majority of nausea, vomiting, and/or diarrhea events occurred during dose escalation and decreased over time."1 Once a patient reaches a stable maintenance dose and has been on it for at least 4 weeks (the time to reach steady-state plasma tirzepatide), gastrointestinal tolerability typically improves substantially.
A few side effects follow different timelines:
- Nausea, vomiting, diarrhea: concentrate during escalation; most resolve or substantially improve within 8-12 weeks of reaching a stable maintenance dose.
- Hair loss: weight-loss-associated; peaks 3-6 months after the rate of weight loss is greatest, then resolves over 6-12 months once weight stabilizes.
- Injection site reactions: usually resolve within 24-72 hours of each injection; chronic or spreading reactions are atypical.
- Constipation: can persist as a chronic issue; dietary fiber, hydration, and laxatives as needed are standard clinical approaches.
For the underlying mechanism on why titration matters, see our tirzepatide dosing guide, the 4-weeks-per-step rule exists specifically because steady-state plasma concentrations take about 4 weeks to establish.
How can you reduce tirzepatide side effects?
A few practical approaches have support from the FDA label's own titration reasoning and standard clinical practice:
- □ Follow the 4-weeks-per-step ladder exactly. Faster escalation concentrates gastrointestinal side effects; the FDA-mandated 4-week interval is designed around steady-state pharmacokinetics.
- □ Eat smaller, more frequent meals. Large meals overload delayed gastric emptying and trigger nausea or vomiting.
- □ Avoid high-fat and fried foods during escalation. Fat slows gastric emptying further and compounds the drug's own motility effect.
- □ Stay hydrated. Vomiting and diarrhea can drive volume depletion and kidney injury; this is one of the label's explicit warnings.
- □ Time the injection strategically. Many patients prefer injecting on a day when they can rest if needed, side effects are often most noticeable in the first 24-48 hours after a dose increase.
- □ Step back rather than push through. The Zepbound label explicitly permits holding at 5 mg or 10 mg as a maintenance dose if a higher maintenance dose is not tolerated.
- □ Report severe or persistent symptoms. Severe abdominal pain, persistent vomiting, signs of dehydration, or any anaphylaxis symptoms warrant urgent medical evaluation.
Does compounded tirzepatide have the same side effects?
The active molecule is the same in compounded and branded tirzepatide, so the class-level side effects are expected to be the same: gastrointestinal reactions during escalation, occasional hair loss with weight reduction, the serious reactions listed in the Zepbound label. What differs is the surrounding data quality and formulation specifics.
Compounded preparations can contain different excipients, buffers, preservatives, or combination ingredients (such as tirzepatide combined with vitamin B12) that are not in the FDA-approved Zepbound vial. Those differences can produce injection site reactions specific to the compounded formulation or effects attributable to the combination ingredient rather than tirzepatide itself. For the current regulatory context on compounded tirzepatide, see our compounded tirzepatide explainer.
Rate data for compounded preparations is not systematically collected the way FDA-mandated clinical trial data is for branded tirzepatide. Patients on compounded formulations should expect roughly the same side-effect profile, report any unusual reactions to the compounding pharmacy and their prescriber, and be aware that FAERS (the FDA Adverse Event Reporting System) is available for postmarketing reports on any tirzepatide product, branded or compounded.
Frequently Asked Questions
What are the bad side effects of tirzepatide?
The most bothersome tirzepatide side effects for most patients are nausea (25-29%), diarrhea (19-23%), and vomiting (8-13%), which concentrate during the dose-escalation phase. The rare serious side effects to watch for are acute pancreatitis, severe abdominal pain, signs of anaphylaxis (throat swelling, widespread rash, difficulty breathing), and severe vomiting or diarrhea leading to dehydration.1
Can you develop tolerance to tirzepatide side effects?
Yes. The FDA label specifically notes that gastrointestinal reactions decrease over time as patients reach steady-state exposure at a given dose. Most patients who tolerate the 4-week escalation steps find side effects improve substantially after reaching a stable maintenance dose. Patients who do not adapt within 8-12 weeks at a maintenance dose should discuss a lower dose with their prescriber.
Should you stop tirzepatide if side effects are severe?
Severe side effects warrant prompt medical attention, not independent discontinuation. For severe abdominal pain, persistent vomiting, signs of dehydration, suspected pancreatitis, or any anaphylaxis symptoms, contact a clinician urgently. For moderate tolerability issues, the FDA label permits holding at a lower maintenance dose rather than stopping, that decision is a conversation with your prescriber.
Are tirzepatide side effects worse than semaglutide?
In the SURMOUNT-5 head-to-head trial, gastrointestinal adverse events were most common in both treatment groups and most were mild to moderate. Rates of treatment discontinuation due to adverse events were comparable between the two drugs. Some patients do substantially better on one drug than the other for reasons that are not predictable in advance. For the full comparison, see our semaglutide vs tirzepatide guide and the full adverse-reaction rate table in our semaglutide side effects breakdown.
Does tirzepatide cause depression or mood changes?
The FDA label describes monitoring for suicidal behavior or ideation as a class-level concern for weight-management medications, based on regulatory caution rather than confirmed trial data for tirzepatide specifically. Patients with a history of depression or suicidal ideation should discuss this with their prescriber before starting. Any new or worsening mood symptoms during treatment warrant prompt clinical attention.
Is tirzepatide safe long-term?
Long-term safety data on tirzepatide continues to accumulate. SURMOUNT-1 followed patients for 72 weeks; Study 4 extended to 88 weeks for a subset. Neither study approaches the decade-plus exposure needed to fully characterize long-term risk. Class-level concerns, thyroid C-cell tumors, pancreatitis, gallbladder disease, are the ones to monitor over years of use, with routine clinical follow-up.
What should you avoid while taking tirzepatide?
Avoid rushing the dose-escalation schedule, large fatty meals during escalation, dehydration, and starting tirzepatide with a personal or family history of medullary thyroid carcinoma or MEN 2. Disclose tirzepatide to surgical and anesthesia teams before any planned procedure because of the pulmonary aspiration risk. Oral contraceptives may be less effective due to delayed gastric emptying, the label recommends a non-oral method or added barrier protection for 4 weeks after initiation and after each dose escalation.1
The Bottom Line
Tirzepatide side effects are dominated by gastrointestinal reactions during the 20-week dose-escalation window. Nausea hits 25-29% of patients, diarrhea 19-23%, vomiting 8-13%, and constipation 11-17%. Most of these are mild to moderate and improve substantially once a patient reaches a stable maintenance dose. Discontinuation rates due to adverse events run 4-7% depending on dose versus 2.6% on placebo. Serious reactions, acute pancreatitis, anaphylaxis, acute kidney injury, gallbladder disease, and the boxed-warning thyroid C-cell tumor risk, exist and warrant monitoring, but are uncommon.
Before starting, changing, or stopping tirzepatide, talk to a licensed prescriber. For the full dosing ladder that the titration rules in this article reference, see our tirzepatide dosing guide. For cost context, our tirzepatide cost guide covers the 2026 pricing map. For the complete tirzepatide overview, start at the tirzepatide hub.
Written By
Rachel Nguyen, MS, RDN
Rachel is a registered dietitian with over a decade of experience in nutrition policy and the economics of health. Her current editorial focus covers GLP-1 medications, obesity medicine, and the intersection of nutrition and pharmaceutical treatment. She holds a Master of Science in Nutrition from the University of North Carolina.
Expert Reviewer
Dr. Kevin Park, PhD
Dr. Park is a nutrition education researcher focused on federal nutrition programs and dietary outcomes. His work has been published in the Journal of School Health and the Journal of the Academy of Nutrition and Dietetics. He reviewed this article's nutrition and public-health content. Clinical decisions about tirzepatide therapy should be made with a licensed prescriber.
Sources
- Eli Lilly and Company. Zepbound (tirzepatide) injection, for subcutaneous use, Full Prescribing Information. FDA-approved label, Section 5 Warnings and Precautions, Section 6 Adverse Reactions (6.1 Clinical Trials Experience, Table 1; 6.2 Postmarketing Experience), and Section 17 Patient Counseling Information. DailyMed SPL setid 487cd7e7-434c-4925-99fa-aa80b1cc776b, SPL version 37 published March 3, 2026. dailymed.nlm.nih.gov. Retrieved .
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. 2022 Jul 21;387(3):205-216. doi:10.1056/NEJMoa2206038. ClinicalTrials.gov NCT04184622. Abstract verified via pubmed.ncbi.nlm.nih.gov/35658024. Retrieved .
- US Food and Drug Administration. FDA Adverse Event Reporting System (FAERS) Public Dashboard. fda.gov. Postmarketing safety surveillance system; referenced for tirzepatide postmarketing reports. Retrieved .
- US National Library of Medicine. MedlinePlus: Tirzepatide Injection. medlineplus.gov. Patient-facing reference maintained by NLM, concordant with the FDA-approved label.